135065-76-8

Basic information

• Product Name: (S)-N-Boc-2-Hydroxymethylmorpholine
• Synonyms: (S)-2-Hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester;N-Boc-(S)-3-morpholine-methanol;(S)-N-BOC-2-HYDROXYMETHYLMORPHOLINE;(S)-4-BOC-2-HYDROXYMETHYL-MORPHOLINE;(2S)-2-hydroxymethyl-morpholine-4-carboxylic acid tert-butyl ester;(S)-N-Boc-2-HydroxyMethyl...;tert-Butyl (2S)-2-(hydroxyMethyl)Morpholine-4-carboxylate;4-Morpholinecarboxylic acid, 2-(hydroxyMethyl)-, 1,1-diMethylethyl ester, (2S)-
• CAS NO: 135065-76-8
• Molecular Formula: C₁₀H₁₉NO₄
• Molecular Weight: 217.26
• EINECS: 1312995-182-4
• Product Categories: pharmacetical;API intermediates;Heterocycle-other series
• Mol File: 135065-76-8.mol

Chemical Properties

• Melting Point: 60-62 °C
• Boiling Point: 321 °C
• Flash Point: 148 °C
• Appearance: White crystal powder
• Density: 1.118
• Vapor Pressure: 2.53E-05mmHg at 25°C
• Refractive Index: 1.474
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 14.36±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• Sensitive: Light Sensitive
• CAS DataBase Reference: (S)-N-Boc-2-Hydroxymethylmorpholine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-Boc-2-Hydroxymethylmorpholine(135065-76-8)
• EPA Substance Registry System: (S)-N-Boc-2-Hydroxymethylmorpholine(135065-76-8)

Safety Data

• Hazardous Substances Data: 135065-76-8(Hazardous Substances Data)

Usage

Uses

(S)-N-Boc-2-hydroxymethylmorpholine is used as a pharmaceutical intermediate.

InChI:InChI=1/C10H19NO4/c1-10(2,3)15-9(13)11-4-5-14-8(6-11)7-12/h8,12H,4-7H2,1-3H3/t8-/m0/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 132073-83-7 (S)-morpholin-2-ylmethanol 
• 847805-30-5 (6S)-6-(hydroxymethyl)morpholin-3-one 
• 847805-29-2 (-)-2-chloro-N-((S)-2,3-dihydroxypropyl)acetamide 
• 132073-82-6 (S)-4-Benzyl-2-(hydroxymethyl)morpholine 
• 148638-77-1 N-Benzyl-2-chloro-N-((S)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-acetamide 
• 148638-78-2 (S)-4-Benzyl-6-hydroxymethyl-morpholin-3-one 
• 135065-72-4 (S)-N-benzyl-3-chloroacetamidopropane-1,2-diol 
• 911223-10-4 (S)-2-benzyloxymethyl-morpholine-4-carboxylic acid tert-butyl ester 
• 868689-63-8 (S)-2,4-morpholinedicarboxylic acid 4-(1,1-dimethylethyl)ester 
• 167357-55-3 (+)-2(S)-(phenylmethyloxymethyl)morpholine 

Downstream Products

• 148638-76-0 tert-butyl (2S)-2-({[(4-methylphenyl)sulfonyl]oxy}methyl)morpholine-4-carboxylate 
• 847805-31-6 (S)-(+)-2-formylmorpholine-4-carboxylic acid tert-butyl ester 
• 847805-33-8 (+)-(2S,3R)-2-[α-hydroxy(phenyl)methyl]morpholine-4-carboxylic acid tert-butyl ester 
• 847805-32-7 (+)-(2S,3S)-2-[α-hydroxy(phenyl)methyl]morpholine-4-carboxylic acid tert-butyl ester 
• 71620-89-8 (S,S)-reboxetine 
• 868689-63-8 (S)-2,4-morpholinedicarboxylic acid 4-(1,1-dimethylethyl)ester 
• 919286-71-8 tert-butyl (2S)-2-(bromomethyl)-4-morpholinecarboxylate 
• 1308849-92-4 (S)-tert-butyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 
• 1308849-86-6 (S)-methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-benzo[d]imidazol-1-yl)methyl)morpholine-4-carboxylate 
• 1489389-18-5 5-[[4-[[(2S)-morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile 
• 1613260-11-9 (S)-tert-butyl 2-((7-(4-morpholinophenyl)pyrido[4,3-b]pyrazin-5-yloxy)methyl)morpholine-4-carboxylate 
• 1613260-12-0 (S)-2-((7-(4-morpholinophenyl)pyrido[4,3-b]pyrazin-5-yloxy)methyl)morpholine 
• 1613260-13-1 (S)-3-chloro-1-(2-((7-(4-morpholinophenyl)pyrido[4,3-b]pyrazin-5-yloxy)methyl)morpholino)propan-1-one 
• 1613258-22-2 (S)-3-(dimethylamino)-1-(2-((7-(4-morpholinophenyl)pyrido[4,3-b]pyrazin-5-yloxy)methyl)morpholino)propan-1-one 

Relevant articles and documents

Radiosynthesis and evaluation of 18F-labeled dopamine D4-receptor ligands

Introduction: The dopamine D4 receptor (D4R) has attracted considerable attention as potential target for the treatment of a broad range of central nervous system disorders. Although many efforts have been made to improve the performance of putative radioligand candidates, there is still a lack of D4R selective tracers suitable for in vivo PET imaging. Thus, the objective of this work was to develop a D4-selective PET ligand for clinical applications. Methods: Four compounds based on previous and new lead structures were prepared and characterized with regard to their D4R subtype selectivity and predicted lipophilicity. From these, 3-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridine I and (S)-4-(3-fluoro-4-methoxybenzyl)-2-(phenoxymethyl)morpholine II were selected for labeling with fluorine-18 and subsequent evaluation by in vitro autoradiography to assess their suitability as D4 radioligand candidates for in vivo imaging. Results: The radiosynthesis of [18F]I and [18F]II was successfully achieved by copper-mediated radiofluorination with radiochemical yields of 7% and 66%, respectively. The radioligand [18F]II showed specific binding in areas where D4 expression is expected, whereas [18F]I did not show any uptake in distinct brain regions and exhibited an unacceptable degree of non-specific binding. Conclusions: The compounds studied exhibited high D4R subtype selectivity and logP values compatible with high brain uptake, but only ligand [18F]II showed low non-specific binding and is therefore a good candidate for further evaluation. Advances in knowledge: The discovery of new lead structures for high-affinity D4 ligands opens up new possibilities for the development of suitable PET-radioligands. Implications for patient: PET-imaging of dopamine D4-receptors could facilitate understanding, diagnosis and treatment of neuropsychiatric and neurodegenerative diseases.

CXCR4 Receptor Antagonists

Disclosed are compounds that are antagonists of the CXCR4 receptor.

Sulfinamides as highly effective amine protecting groups and their use in the conversion of Amino alcohols into morpholines

1,2-Amino alcohols have been converted into morpholines by using sulfinamides as temporary protecting/activating groups on the amine. We have developed a procedure for the selective synthesis of monoprotected N-sulfinyl amino alcohols through a double sul

BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF

The present invention discloses novel benzamide derivatives represented by general formula (I), their preparation, pharmaceutical compositions containing the derivatives and their use as medicament, especially as a 5-HT4 stimulator, wherein the

BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF

The present invention discloses novel benzamide derivatives represented by general formula (I), their preparation, pharmaceutical compositions containing the derivatives and their use as medicament, especially as a 5-HT4 stimulator, wherein the

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS

The present application relates to cannabinoid receptor ligands of formula (I) wherein X1, A1, Rx, R2, R3, R4, and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.

PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin- 2 - yl -pyridin- 2 -yl -amine and pyrazine - 2 - yl -pyrimidin- 4 - yl -amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1 ) kinase function The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1. that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or Il inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionisiπq radiation. wherein: -X= is independently -CRA5= or -N=; and the rest of the substituents are as specified in the claims.

PIPERAZINES AS ANTI-OBESITY AGENTS

The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds, to processes for their preparation, and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.

Concise synthesis of (S)-N-BOC-2-hydroxymethylmorpholine and (S)-N-BOC-morpholine-2-carboxylic acid

(Chemical Equation Presented) An operationally simple synthesis of N-BOC-2-hydroxymethylmorpholine (1) and N-BOC-morpholine-2-carboxylic acid (2) from epichlorohydrin has been developed. No chromatography is required in the processing, which allows high p